RU2579513C2 - Ингибиторы активности акт - Google Patents

Ингибиторы активности акт Download PDF

Info

Publication number
RU2579513C2
RU2579513C2 RU2012131115/04A RU2012131115A RU2579513C2 RU 2579513 C2 RU2579513 C2 RU 2579513C2 RU 2012131115/04 A RU2012131115/04 A RU 2012131115/04A RU 2012131115 A RU2012131115 A RU 2012131115A RU 2579513 C2 RU2579513 C2 RU 2579513C2
Authority
RU
Russia
Prior art keywords
phenyl
pyrido
oxazin
aminocyclobutyl
dihydro
Prior art date
Application number
RU2012131115/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2012131115A (ru
Inventor
Лисинь ЧЖАН
Грэхем Питер ТРЕВИТТ
Юг МИЭЛЬ
Франк Буркамп
Тимоти Харрисон
Эндрю Джон УИЛКИНСОН
Шарль-Анри ФАБРИТИУС
Original Assignee
Олмак Дискавери Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Олмак Дискавери Лимитед filed Critical Олмак Дискавери Лимитед
Publication of RU2012131115A publication Critical patent/RU2012131115A/ru
Application granted granted Critical
Publication of RU2579513C2 publication Critical patent/RU2579513C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2012131115/04A 2009-12-23 2010-12-23 Ингибиторы активности акт RU2579513C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0922589.7A GB0922589D0 (en) 2009-12-23 2009-12-23 Pharmaceutical compounds
GB0922589.7 2009-12-23
PCT/GB2010/002329 WO2011077098A1 (en) 2009-12-23 2010-12-23 Inhibitors of akt activity

Publications (2)

Publication Number Publication Date
RU2012131115A RU2012131115A (ru) 2014-01-27
RU2579513C2 true RU2579513C2 (ru) 2016-04-10

Family

ID=41716932

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012131115/04A RU2579513C2 (ru) 2009-12-23 2010-12-23 Ингибиторы активности акт

Country Status (22)

Country Link
US (1) US9221838B2 (hr)
EP (1) EP2516435B8 (hr)
JP (1) JP5923043B2 (hr)
KR (1) KR20140015157A (hr)
CN (1) CN102791708B (hr)
AU (1) AU2010334591C1 (hr)
BR (1) BR112012015677A2 (hr)
CA (1) CA2783340C (hr)
CY (1) CY1115686T1 (hr)
DK (1) DK2516435T3 (hr)
ES (1) ES2503794T3 (hr)
GB (1) GB0922589D0 (hr)
HK (1) HK1171013A1 (hr)
IL (1) IL220153A (hr)
MX (1) MX2012007274A (hr)
NZ (1) NZ600453A (hr)
PL (1) PL2516435T3 (hr)
PT (1) PT2516435E (hr)
RU (1) RU2579513C2 (hr)
SG (1) SG181517A1 (hr)
SI (1) SI2516435T1 (hr)
WO (1) WO2011077098A1 (hr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2815372C2 (ru) * 2017-09-07 2024-03-13 Огаста Юниверсити Рисерч Инститьют, Инк. Специфический активатор akt3 и его применение
US11957673B2 (en) 2017-09-07 2024-04-16 Augusta University Research Institute, Inc. Specific AKT3 activator and uses thereof

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201205164D0 (en) * 2012-03-23 2012-05-09 Almac Discovery Ltd Pharmaceutical compounds
CA2971763A1 (en) * 2014-12-23 2016-06-30 Bergenbio Asa Inhibitors of akt kinase
CN107428779A (zh) * 2015-02-27 2017-12-01 大鹏药品工业株式会社 咪唑并噁嗪晶体、含有所述晶体的药物组合物和制备所述晶体的方法
GB201603779D0 (en) 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
WO2018031407A1 (en) 2016-08-07 2018-02-15 The Wistar Institute Of Anatomy And Biology Methods of detecting and treating a tumor expressing pt346 pdk1
MX2019015468A (es) * 2017-06-22 2020-08-03 Curadev Pharma Ltd Moduladores de moleculas pequeñas de sting humana.
GB2600384A (en) 2020-09-30 2022-05-04 Vaderis Therapeutics Ag Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2191188C2 (ru) * 1994-11-14 2002-10-20 Варнер-Ламберт Компани Производные 6-арилпиридо[2,3-d]-пиримидины и -нафтиридины, фармацевтическая композиция, обладающая ингибирующим действием клеточной пролиферации, вызываемой протеиновой тирозинкиназой, и способ ингибирования клеточной пролиферации

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI301760B (en) * 2004-02-27 2008-10-11 Merz Pharma Gmbh & Co Kgaa Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors
AU2005316826A1 (en) * 2004-12-15 2006-06-22 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
CA2610888C (en) * 2005-06-10 2011-02-08 Merck & Co., Inc. Inhibitors of akt activity
CA2656507C (en) * 2006-07-17 2012-03-20 Amgen Inc. Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
EP2120951A4 (en) 2006-12-06 2012-02-15 Merck Sharp & Dohme INHIBITORS OF AKT ACTIVITY
US7999107B2 (en) * 2007-01-31 2011-08-16 Merck Sharp & Dohme Corp. Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
WO2009148887A1 (en) 2008-06-03 2009-12-10 Merck & Co., Inc. Inhibitors of akt activity
CA2726317A1 (en) * 2008-06-03 2009-12-10 Merck Sharp & Dohme Corp. Inhibitors of akt activity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2191188C2 (ru) * 1994-11-14 2002-10-20 Варнер-Ламберт Компани Производные 6-арилпиридо[2,3-d]-пиримидины и -нафтиридины, фармацевтическая композиция, обладающая ингибирующим действием клеточной пролиферации, вызываемой протеиновой тирозинкиназой, и способ ингибирования клеточной пролиферации

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Wu Z. et al., Rapid assembly of diverse and potent allosteric Akt inhibitors, Bioorganic & Medicinal Chemistry Letters, 2008, vol.18, no.6, p.2211-2214. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2815372C2 (ru) * 2017-09-07 2024-03-13 Огаста Юниверсити Рисерч Инститьют, Инк. Специфический активатор akt3 и его применение
US11957673B2 (en) 2017-09-07 2024-04-16 Augusta University Research Institute, Inc. Specific AKT3 activator and uses thereof

Also Published As

Publication number Publication date
CA2783340C (en) 2015-11-24
MX2012007274A (es) 2012-10-03
JP2013515710A (ja) 2013-05-09
ES2503794T3 (es) 2014-10-07
AU2010334591A1 (en) 2012-06-21
DK2516435T3 (da) 2014-10-13
HK1171013A1 (en) 2013-03-15
EP2516435B8 (en) 2014-10-15
BR112012015677A2 (pt) 2015-06-30
CN102791708B (zh) 2016-03-02
WO2011077098A1 (en) 2011-06-30
NZ600453A (en) 2013-10-25
US20130116243A1 (en) 2013-05-09
SI2516435T1 (sl) 2014-12-31
IL220153A0 (en) 2012-07-31
JP5923043B2 (ja) 2016-05-24
GB0922589D0 (en) 2010-02-10
PT2516435E (pt) 2014-11-13
WO2011077098A9 (en) 2012-04-19
KR20140015157A (ko) 2014-02-06
PL2516435T3 (pl) 2015-01-30
CY1115686T1 (el) 2017-01-25
CA2783340A1 (en) 2011-06-30
RU2012131115A (ru) 2014-01-27
EP2516435B1 (en) 2014-08-06
SG181517A1 (en) 2012-07-30
AU2010334591C1 (en) 2014-07-31
IL220153A (en) 2015-05-31
AU2010334591B2 (en) 2014-04-10
CN102791708A (zh) 2012-11-21
EP2516435A1 (en) 2012-10-31
US9221838B2 (en) 2015-12-29

Similar Documents

Publication Publication Date Title
RU2579513C2 (ru) Ингибиторы активности акт
US8546376B2 (en) Pharmaceutical compounds
AU2016243939A1 (en) Heterocyclic compounds as LSD1 inhibitors
WO2016007736A1 (en) Imidazopyrazines as lsd1 inhibitors
WO2015140051A1 (en) Heteroaryl sik inhibitors
CA3210332A1 (en) Tricyclic-amido-bicyclic prmt5 inhibitors
EP2488519A1 (en) Pyrazolopyridine derivatives as anticancer agent
US20120309739A1 (en) Akt / pkb inhibitors
US9156853B2 (en) AKT inhibitor compounds for treatment of cancer
KR20200081436A (ko) 파르네소이드 x 수용체 조정제로서의 알켄 화합물
JP5937201B2 (ja) ２−アミノ−３−（イミダゾール−２−イル）ピリジン−４−オン誘導体及びｖｅｇｆ受容体キナーゼ阻害剤としてのその使用
JP7357146B2 (ja) アザヘテロアリール化合物及びその使用
CN110461849B (zh) 一种csf1r抑制剂及其制备方法和应用
KR20160086930A (ko) 피롤로피롤론 유도체 및 bet 억제제로서의 그의 용도
AU2020380828A1 (en) WDR5 inhibitors and modulators
TW202312995A (zh) 氮雜芳基化合物、其製備方法及應用

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20171224